Fig. 6From: Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathwaySFN enhances the antitumor ability of CAR-T cells in patients with cancer. A Time line of immunotherapy treatment. B The expression of PD-1 on CD8+ CAR-T cells derived from patients who had or had not received sulforaphane (SFN) at different time points. D, E The expression of IFN-γ and IL-2 in CD8+ CAR-T cells derived from patients who had or had not received SFN on day 2, 7, 14, and 21. *, P < 0.05; **, P < 0.01 (Student’s t test)Back to article page